Coherence Neuro reportedly completes 45000000 USD Series A financing and plans to advance long-term human implant trials

AT A GLANCE

Reports state that Coherence Neuro has completed 45000000 USD Series A financing and is developing an implantable device for monitoring and stimulating brain tumors.

Article

OpenAI Fund co-leads cancer brain-computer interface investment: reads tumor electrical signals and attempts to inhibit growth with electrical stimulation

Beating AI Breaking News: U.S. neurotechnology company Coherence Neuro has completed 45000000 USD Series A financing, co-led by OpenAI Startup Fund and Peter Thiel's Founders Fund, with Lux Capital、8VC and others participating in the investment.

Unlike Neuralink, which primarily helps paralyzed patients control devices, Coherence aims to use a brain-computer interface to directly monitor cancer and even inhibit tumor growth through electrical stimulation.

Its technical premise is that brain tumors do not grow solely within tissue; they also exchange electrical signals with surrounding neurons and alter brain electrical activity. Coherence is developing an implantable device called SOMA, which continuously reads these signals through electrodes and then uses AI to assess tumor changes and adjust electrical stimulation protocols.

The complete system includes a coin-sized brain implant, a behind-the-ear power device, and a mobile app. The ultimate goal is to enable patients to receive around-the-clock monitoring and personalized treatment at home, rather than relying entirely on periodic scans to understand their condition.

Research published by the team this year July shows that long-term recording of brain electrical activity in mice with cancer can predict tumor growth rates over approximately 5 weeks. This year June, the team also initiated human trials at Royal Melbourne Hospital in Australia. The first patients received approximately 30 minutes of temporary electrode testing only during brain tumor resection surgery. It is currently advancing recording and stimulation testing in another 7 patients.

Electric field therapy for cancer is not an entirely new concept. The U.S.FDA has long approved the external electric field therapy device Optune for certain patients with glioblastoma. Coherence aims to further integrate monitoring and treatment into an implant, using real-time data to continuously adjust interventions.

The new financing will support its first long-term human implant trial and advance preclinical research into other cancers, including pancreatic cancer.

Original link https://m.theblockbeats.info/flash/373169

Key points

Beating AI reports that U.S. neurotechnology company Coherence Neuro has completed 45000000 USD Series A financing.
The financing round was co-led by OpenAI Startup Fund and Peter Thiel's Founders Fund, with Lux Capital、8VC and others participating in the investment.
Coherence Neuro is developing an implantable device called SOMA, which continuously reads signals through electrodes and then uses AI to assess tumor changes and adjust electrical stimulation protocols.
The system described in the report includes a coin-sized brain implant, a behind-the-ear power device, and a mobile app.
The report claims that research published by the team this year July can predict tumor growth rates over approximately 5 weeks by long-term recording of brain electrical activity in mice with cancer.
The report claims that the team this year June initiated human trials at Royal Melbourne Hospital in Australia. The first patients received approximately 30 minutes of temporary electrode testing during brain tumor resection surgery, and the team is currently advancing recording and stimulation testing in another 7 patients.
The new financing will support the first long-term human implant trial and advance preclinical research into other cancers, including pancreatic cancer.

AI-assisted interpretation

The following is analysis, separate from reported facts. Verify important claims independently.

The company aims to implant electrodes in the brain to continuously observe electrical signals associated with brain tumors and attempt to adjust electrical stimulation based on the data. The currently described evidence consists primarily of financing, animal research, and a small number of short-duration human tests, and does not yet demonstrate that this approach can safely and effectively inhibit tumors in humans.

Why it matters to readers

If subsequent trials can validate safety and efficacy, this device could combine tumor electrical-signal monitoring with stimulation interventions and reduce complete reliance on periodic scans; however, the long-term human implant trial described in the original article has yet to proceed.

Beginners should distinguish between “securing funding and launching early testing” and “the treatment has already proven effective.” Funding indicates that the project has received financial support; it does not mean the device has passed clinical validation or been approved for use.

Risks and unknowns

Information on the financing and investors appears only in the provided media report; the evidence contains no formal announcement.
The evidence does not provide relevant research papers, trial registrations, or complete data, and the animal-study results cannot be verified here.
The first patients received only approximately 30 minutes of temporary electrode testing; the safety and efficacy of long-term implantation are unknown.

Coherence Neuro reportedly completes 45000000 USD Series A financing and plans to advance long-term human implant trials

Article

AI-assisted interpretation

Why it matters to readers

Risks and unknowns

Related Developments

Related concepts

Keep following

Security Center